Randomization

Global eClinical Solutions Market Report 2023: Increased Government Grants to Support Clinical Trials Drives Growth

Retrieved on: 
Wednesday, June 28, 2023

Global eClinical Solutions Market, by Pharma and Biopharma Companies, by Region, 2019-2032 (USD Billion)

Key Points: 
  • Global eClinical Solutions Market, by Pharma and Biopharma Companies, by Region, 2019-2032 (USD Billion)
    8.2.1.
  • Global eClinical Solutions Market, by Electronic Clinical Outcome Assessment (ECOA), by Region, 2019-2032 (USD Billion)
    8.4.1.
  • Global eClinical Solutions Market, by Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS), by Region, 2019-2032 (USD Billion)
    8.6.1.
  • Global eClinical Solutions Market, by Clinical Trial Management Systems (CTMS), by Region, 2019-2032 (USD Billion)
    8.9.1.

Global Interactive Response Technology (IRT) Benchmarking & Market Dynamics Report 2022 - Gain an Understanding of the IRT Solutions Being Utilized Most by Peers

Retrieved on: 
Sunday, January 22, 2023

DUBLIN, Jan. 22, 2023 /PRNewswire/ -- The "IRT Benchmarking & Market Dynamics (4th Ed)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 22, 2023 /PRNewswire/ -- The "IRT Benchmarking & Market Dynamics (4th Ed)" report has been added to ResearchAndMarkets.com's offering.
  • The Interactive Response Technology (IRT) space, also sometimes called Randomization and Trial Supply Management (RTSM), has continued to evolve since 2014.
  • There are few dedicated IRT providers left among the market leaders, and customers continue to value integration with EDC, CTMS, eCOA, and other technologies above all else.
  • The clinical technology industry continues to see a lot of change, including mergers, acquisitions, and spin-offs among leaders in the space.

Global Interactive Response Technology (IRT) Benchmarking & Market Dynamics Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023

The "IRT Benchmarking & Market Dynamics (4th Ed)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "IRT Benchmarking & Market Dynamics (4th Ed)" report has been added to ResearchAndMarkets.com's offering.
  • The Interactive Response Technology (IRT) space, also sometimes called Randomization and Trial Supply Management (RTSM), has continued to evolve since 2014.
  • There are few dedicated IRT providers left among the market leaders, and customers continue to value integration with EDC, CTMS, eCOA, and other technologies above all else.
  • The clinical technology industry continues to see a lot of change, including mergers, acquisitions, and spin-offs among leaders in the space.

Medrio Completes Successful Type 2 System and Organization Controls (SOC) 2 Examination

Retrieved on: 
Monday, August 22, 2022

SAN FRANCISCO, Aug. 22, 2022 /PRNewswire-PRWeb/ -- Medrio, a global leader in eClinical software and services used in decentralized, hybrid, and traditional clinical trials, has successfully completed a System and Organization Controls (SOC) 2 Type 2 examination. The independent third-party report attests to the controls at Medrio regarding the security, availability, and confidentiality of its eClinical technology and solutions.

Key Points: 
  • Medrio, a global leader in eClinical software and services used in decentralized, hybrid, and traditional clinical trials, has successfully completed a System and Organization Controls (SOC) 2 Type 2 examination.
  • The independent third-party report attests to the controls at Medrio regarding the security, availability, and confidentiality of its eClinical technology and solutions.
  • SAN FRANCISCO, Aug. 22, 2022 /PRNewswire-PRWeb/ -- Medrio, a global leader in eClinical software and services used in decentralized, hybrid, and traditional clinical trials, has successfully completed a System and Organization Controls (SOC) 2 Type 2 examination.
  • The independent third-party report attests to the controls at Medrio regarding the security, availability, and confidentiality of its eClinical technology and solutions.

Axiom Exhibiting and Presenting “Saving People’s Lives – The Value of Time” at DIA Global Annual Meeting 2022

Retrieved on: 
Monday, June 20, 2022

TORONTO, June 20, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), the premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at DIA 2022 June 20-22 in Chicago, Il.

Key Points: 
  • TORONTO, June 20, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), the premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at DIA 2022 June 20-22 in Chicago, Il.
  • Coupled with their expansive DM/Clinical Research/Safety/Biostats and Data Analytics services, Fusion and Axiom can enable clients to manage clinical studies.
  • "Axiom is thrilled to be in person at the DIA Annual Meeting once again.
  • Presenting Saving Patient Lives The Value of Time, Axioms Andrew Shachter, Founder and CEO will be sharing his insights on June 22nd at 3:10PM CST.

Axiom Presenting “Key Randomization & Trial Supply Considerations: Starting your study on the right foot!” at Clinical Trial Supply West Coast 2022

Retrieved on: 
Monday, April 11, 2022

For this years program, delegates can attend two different streams: Clinical Trial Supply Operations and Clinical Trial Supply Innovation & Technology.

Key Points: 
  • For this years program, delegates can attend two different streams: Clinical Trial Supply Operations and Clinical Trial Supply Innovation & Technology.
  • This conference brings together pharmaceutical and biotech experts to explore key themes and opportunities to optimize clinical supply chains, inclusive of RTSM, IRT, Inventory Management and simplifying these key processes.
  • Presenting Key Randomization & Trial Supply Considerations: Starting your study on the right foot!, Axioms Heather DiFruscia, VP, Randomization and Trial Supply Management will be sharing her insights on April 14th at 2:00PM PDT.
  • The Randomization and Trial Supply Management Modules are core to Axioms Fusion eClinical Suite and fully configurable to the needs of each study.

E-Clinical Solutions Market size worth $ 16.5 Billion, Globally, by 2028 at 12.4% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, January 19, 2022

According to Verified Market Research, the Global E-Clinical Solutions Market size was valued at USD 6.5 Billion in 2020 and is projected to reach USD 16.5 Billion by 2028, growing at a CAGR of 12.4% from 2021 to 2028.

Key Points: 
  • According to Verified Market Research, the Global E-Clinical Solutions Market size was valued at USD 6.5 Billion in 2020 and is projected to reach USD 16.5 Billion by 2028, growing at a CAGR of 12.4% from 2021 to 2028.
  • The rising prevalence of chronic and lifestyle-related disorders, as well as the growing elderly population, are some factors propelling the E-Clinical Solutions Market forward.
  • Although e-clinical solutions are expensive, CROs, healthcare providers, and pharmaceutical and biotechnology companies are hesitant to utilize the technology.
  • Verified Market Research has segmented the Global E-Clinical Solutions Market On the basis of Type, Delivery Mode, and Geography.

E-Clinical Solutions Market size worth $ 16.5 Billion, Globally, by 2028 at 12.4% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, January 19, 2022

JERSEY CITY, N.J., Jan. 19, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "E-Clinical Solutions Market" By Type (Clinical Data Management System, Randomization and Trial Supply Management, Electronic Clinical Outcome Assessment), By Delivery Mode (Web-Based and Cloud-Based, Enterprise-Based), and By Geography. According to Verified Market Research, the Global E-Clinical Solutions Market size was valued at USD 6.5 Billion in 2020 and is projected to reach USD 16.5 Billion by 2028, growing at a CAGR of 12.4% from 2021 to 2028.

Key Points: 
  • JERSEY CITY, N.J., Jan. 19, 2022 /PRNewswire/ --Verified Market Research recently published a report, " E-Clinical Solutions Market " By Type (Clinical Data Management System, Randomization and Trial Supply Management, Electronic Clinical Outcome Assessment), By Delivery Mode (Web-Based and Cloud-Based, Enterprise-Based), and By Geography.
  • According to Verified Market Research, the Global E-Clinical Solutions Market size was valued at USD 6.5 Billion in 2020 and is projected to reach USD 16.5 Billion by 2028, growing at a CAGR of 12.4% from 2021 to 2028.
  • The rising prevalence of chronic and lifestyle-related disorders, as well as the growing elderly population, are some factors propelling the E-Clinical Solutions Market forward.
  • Verified Market Research has segmented the Global E-Clinical Solutions Market On the basis of Type, Delivery Mode, and Geography.

Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum

Retrieved on: 
Wednesday, July 28, 2021

DURHAM, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the last patient has completed their planned Week-24 follow-up visit in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical gel with antiviral properties for the treatment of molluscum contagiosum (“molluscum”).

Key Points: 
  • Tomoko Maeda-Chubachi, M.D., Ph.D., M.B.A., Senior Vice President, Medical at Novan commented, The completion of all Week-24 patient visits is an exciting step forward towards bringing a promising treatment option to molluscum patients.
  • B-SIMPLE4 is a multi-center, double-blind, randomized, vehicle-controlled study that exceeded its enrollment target by randomizing 891 patients (1:1 randomization) in the study, across 55 clinical sites.
  • Patients were treated for up to 12 weeks with a follow-up visit at Week 24.
  • The Companys lead product candidate is SB206, a topical gel with antiviral properties, for the treatment of molluscum.

OmniComm Systems Releases IRTMaster Version 5.2, a Customizable Interactive Response Technology System for Streamlined Clinical Trial and Supply Management

Retrieved on: 
Monday, November 25, 2019

IRTMaster is a fully configurable Interactive Responsive Technology (IRT) system that enables subject screening and randomization, clinical supply management, and investigational product assignment at designated drug dispensing visits.

Key Points: 
  • IRTMaster is a fully configurable Interactive Responsive Technology (IRT) system that enables subject screening and randomization, clinical supply management, and investigational product assignment at designated drug dispensing visits.
  • IRTMaster is specifically designed to reduce the burden of setting up randomization and managing drug supplies within a clinical trial, said Stephen Johnson, chief revenue officer at OmniComm.
  • OmniComms proprietary EDC and eClinical software applications TrialMaster, TrialOne, eClinical Suite, Promasys, IRTMaster, AutoEncoder and Acuity allow clinical trial sponsors and investigative sites to securely collect, validate, transmit and analyze clinical trial data.
  • For more information about OmniComm, visit: www.omnicomm.com
    Contact Kuno van der Post OmniComm Systems, Inc.